Sensei Labs

Sensei Biotherapeutics is a clinical-stage immuno-oncology company focused on discovering and developing next-generation therapeutics for cancer patients. The company utilizes its proprietary TMAb (Tumor Microenvironment Activated biologics) platform to create conditionally active antibodies designed to selectively target the acidic environment of tumors, thereby minimizing systemic toxicity. Its lead clinical candidate, solnerstotug (SNS-101), is a monoclonal antibody targeting the immune checkpoint VISTA. Following the acquisition of Faeth Therapeutics, the company also added PIKTOR, a multi-node inhibitor of the PI3K/AKT/mTOR pathway, to its oncology pipeline. As of late 2025, the company has announced strategic shifts, including the wind-down of certain clinical trials to preserve cash and explore strategic alternatives.